Ifosfamide is a produg used in combination chemotherapy for the treatment of solid tumors. Around 20% of patients experience toxicity. Pathways depicting the genes involved in the pharmacokinetics and pharmacodynamics of ifosfamide have been published in PG&G. Variants in these genes that are associated with toxicity and drug resistance are discussed.
Click on the pictures to view the pathways:
 |
Pharmacokinetics |
 |
Pharmacodynamics |
Read the publication:
PharmGKB summary: ifosfamide pathways, pharmacokinetics and pharmacodynamics.
Lowenberg D, Thorn CF, Desta Z, Flockhart DA, Altman RB, Klein TE.
Pharmacogenetics & Genomics. 2014 Feb;24(2):133-8.